EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (Amex: AIS) announced receipt of notice of allowance from the United States Patent & Trademark Office (USPTO) covering the formulation used in Elestrin™ (estradiol gel) which was co-invented by Antares and our licensee, BioSante. The USPTO has stated that it intends to grant patent protection which covers the proprietary formulation used in Elestrin. The patent is expected to expire in 2021.
